Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 147

1.

Endoscopic surveillance or ablation for Barrett's esophagus?

Inadomi JM, Saxena N.

Transl Gastroenterol Hepatol. 2018 Dec 6;3:102. doi: 10.21037/tgh.2018.11.09. eCollection 2018. Review.

2.

Low-Value Colorectal Cancer Screening: Too Much of a Good Thing?

Issaka RB, Inadomi JM.

JAMA Netw Open. 2018 Dec 7;1(8):e185445. doi: 10.1001/jamanetworkopen.2018.5445. No abstract available.

PMID:
30646272
3.

Implications of Epigenetic Drift in Colorectal Neoplasia.

Luebeck GE, Hazelton WD, Curtius K, Maden SK, Yu M, Carter KT, Burke W, Lampe PD, Li CI, Ulrich CM, Newcomb PA, Westerhoff M, Kaz AM, Luo Y, Inadomi JM, Grady WM.

Cancer Res. 2019 Feb 1;79(3):495-504. doi: 10.1158/0008-5472.CAN-18-1682. Epub 2018 Oct 5.

PMID:
30291105
4.

Screening and Surveillance for Barrett's Esophagus: Is It Cost-Effective?

Inadomi JM, Saxena N.

Dig Dis Sci. 2018 Aug;63(8):2094-2104. doi: 10.1007/s10620-018-5148-7. Review.

PMID:
29948571
5.

Quality indicators for gastrointestinal endoscopy units.

ASGE Endoscopy Unit Quality Indicator Taskforce, Day LW, Cohen J, Greenwald D, Petersen BT, Schlossberg NS, Vicari JJ, Calderwood AH, Chapman FJ, Cohen LB, Eisen G, Gerstenberger PD, Hambrick RD 3rd, Inadomi JM, MacIntosh D, Sewell JL, Valori R.

VideoGIE. 2017 May 26;2(6):119-140. doi: 10.1016/j.vgie.2017.02.007. eCollection 2017 Jun. No abstract available.

6.

The Effect of Endoscopic Surveillance in Patients With Barrett's Esophagus: A Systematic Review and Meta-analysis.

Codipilly DC, Chandar AK, Singh S, Wani S, Shaheen NJ, Inadomi JM, Chak A, Iyer PG.

Gastroenterology. 2018 Jun;154(8):2068-2086.e5. doi: 10.1053/j.gastro.2018.02.022. Epub 2018 Feb 16. Review.

PMID:
29458154
7.

Association of gastric intestinal metaplasia and East Asian ethnicity with the risk of gastric adenocarcinoma in a U.S. population.

Choi AY, Strate LL, Fix MC, Schmidt RA, Ende AR, Yeh MM, Inadomi JM, Hwang JH.

Gastrointest Endosc. 2018 Apr;87(4):1023-1028. doi: 10.1016/j.gie.2017.11.010. Epub 2017 Nov 16.

PMID:
29155082
8.

Surgical vs Endoscopic Management of T1 Esophageal Adenocarcinoma: A Modeling Decision Analysis.

Chu JN, Choi J, Tramontano A, Morse C, Forcione D, Nishioka NS, Abrams JA, Rubenstein JH, Kong CY, Inadomi JM, Hur C.

Clin Gastroenterol Hepatol. 2018 Mar;16(3):392-400.e7. doi: 10.1016/j.cgh.2017.10.024. Epub 2017 Nov 24.

PMID:
29079222
9.

Time to Diagnostic Testing After a Positive Colorectal Cancer Screening Test-Reply.

Rutter CM, Inadomi JM.

JAMA. 2017 Aug 1;318(5):483-484. doi: 10.1001/jama.2017.9316. No abstract available.

PMID:
28763547
10.

Overuse of Repeat Upper Endoscopy in the Veterans Health Administration: A Retrospective Analysis.

Rubenstein JH, Pohl H, Adams MA, Kerr E, Holleman R, Vijan S, Dominitz JA, Inadomi JM, Provenzale D, Francis J, Saini SD.

Am J Gastroenterol. 2017 Nov;112(11):1678-1685. doi: 10.1038/ajg.2017.192. Epub 2017 Jul 11.

PMID:
28695907
11.

Effectiveness and Cost-Effectiveness of Endoscopic Screening and Surveillance.

Saxena N, Inadomi JM.

Gastrointest Endosc Clin N Am. 2017 Jul;27(3):397-421. doi: 10.1016/j.giec.2017.02.005. Epub 2017 Apr 4. Review.

PMID:
28577764
12.

Follow-up of Positive Fecal Test Results: Sooner Is Better, but How Much Better?

Rutter CM, Inadomi JM.

JAMA. 2017 Apr 25;317(16):1627-1628. doi: 10.1001/jama.2017.3629. No abstract available.

PMID:
28444260
13.

Screening for Colorectal Neoplasia.

Inadomi JM.

N Engl J Med. 2017 Apr 20;376(16):1599-1600. doi: 10.1056/NEJMc1702535. No abstract available.

PMID:
28423294
14.

The Impact of a Prior Diagnosis of Barrett's Esophagus on Esophageal Adenocarcinoma Survival.

Tramontano AC, Sheehan DF, Yeh JM, Kong CY, Dowling EC, Rubenstein JH, Abrams JA, Inadomi JM, Schrag D, Hur C.

Am J Gastroenterol. 2017 Aug;112(8):1256-1264. doi: 10.1038/ajg.2017.82. Epub 2017 Apr 4.

15.

Cost Effectiveness of Screening Patients With Gastroesophageal Reflux Disease for Barrett's Esophagus With a Minimally Invasive Cell Sampling Device.

Heberle CR, Omidvari AH, Ali A, Kroep S, Kong CY, Inadomi JM, Rubenstein JH, Tramontano AC, Dowling EC, Hazelton WD, Luebeck EG, Lansdorp-Vogelaar I, Hur C.

Clin Gastroenterol Hepatol. 2017 Sep;15(9):1397-1404.e7. doi: 10.1016/j.cgh.2017.02.017. Epub 2017 Feb 24.

16.

Editorial: Endoscopic Sedation: Who, Which, When?

Inadomi JM.

Am J Gastroenterol. 2017 Feb;112(2):303-305. doi: 10.1038/ajg.2016.557.

PMID:
28154379
17.

Radiofrequency Ablation of Barrett's Esophagus Reduces Esophageal Adenocarcinoma Incidence and Mortality in a Comparative Modeling Analysis.

Kroep S, Heberle CR, Curtius K, Kong CY, Lansdorp-Vogelaar I, Ali A, Wolf WA, Shaheen NJ, Spechler SJ, Rubenstein JH, Nishioka NS, Meltzer SJ, Hazelton WD, van Ballegooijen M, Tramontano AC, Gazelle GS, Luebeck EG, Inadomi JM, Hur C.

Clin Gastroenterol Hepatol. 2017 Sep;15(9):1471-1474. doi: 10.1016/j.cgh.2016.12.034. Epub 2017 Jan 12. No abstract available.

18.

Screening for Colorectal Neoplasia.

Inadomi JM.

N Engl J Med. 2017 Jan 12;376(2):149-156. doi: 10.1056/NEJMcp1512286. Review. No abstract available.

PMID:
28076720
19.

Taxonomy for colorectal cancer screening promotion: Lessons from recent randomized controlled trials.

Ritvo P, Myers RE, Serenity M, Gupta S, Inadomi JM, Green BB, Jerant A, Tinmouth J, Paszat L, Pirbaglou M, Rabeneck L.

Prev Med. 2017 Aug;101:229-234. doi: 10.1016/j.ypmed.2016.12.024. Epub 2016 Dec 24.

PMID:
28024865
20.

Increased Post-procedural Non-gastrointestinal Adverse Events After Outpatient Colonoscopy in High-risk Patients.

Johnson DA, Lieberman D, Inadomi JM, Ladabaum U, Becker RC, Gross SA, Hood KL, Kushins S, Pochapin M, Robertson DJ.

Clin Gastroenterol Hepatol. 2017 Jun;15(6):883-891.e9. doi: 10.1016/j.cgh.2016.12.015. Epub 2016 Dec 23.

PMID:
28017846
21.

Introduction of Clinical Practice Update Committee Articles.

Friedman LS, Inadomi JM, Kalloo AM, Katzka DA, Kim LS, Koch J, Lieberman D, Lichtenstein GR, Lim JK, Pandolfino JE, Shin AS, Siedler MR.

Clin Gastroenterol Hepatol. 2017 Jan;15(1):4. doi: 10.1016/j.cgh.2016.11.011. Review. No abstract available.

PMID:
27979048
22.

Screening for Colorectal Cancer and Evolving Issues for Physicians and Patients: A Review.

Lieberman D, Ladabaum U, Cruz-Correa M, Ginsburg C, Inadomi JM, Kim LS, Giardiello FM, Wender RC.

JAMA. 2016 Nov 22;316(20):2135-2145. doi: 10.1001/jama.2016.17418. Review.

PMID:
27893135
23.

A simple scoring system to assess the need for an endoscopic intervention in suspected upper gastrointestinal bleeding: A prospective cohort study.

Horibe M, Kaneko T, Yokogawa N, Yokota T, Okawa O, Nakatani Y, Ogura Y, Matsuzaki J, Iwasaki E, Hosoe N, Masaoka T, Inadomi JM, Suzuki H, Kanai T, Namiki S.

Dig Liver Dis. 2016 Oct;48(10):1180-6. doi: 10.1016/j.dld.2016.07.009. Epub 2016 Jul 18.

PMID:
27507771
24.

Reply.

Wernli KJ, Brenner AT, Rutter CM, Inadomi JM.

Gastroenterology. 2016 Sep;151(3):564. doi: 10.1053/j.gastro.2016.07.041. Epub 2016 Aug 3. No abstract available.

PMID:
27496674
25.

Colorectal Cancer Screening: Which Test Is Best?

Inadomi JM.

JAMA Oncol. 2016 Aug 1;2(8):1001-3. doi: 10.1001/jamaoncol.2016.2494. No abstract available.

PMID:
27305648
26.

Introduction to Clinical Practice Update Committee Articles.

Katzka DA, Friedman LS, Inadomi JM, Kalloo AM, Kim LS, Koch J, Lieberman D, Lichtenstein GR, Lim JK, Pandolfino JE, Shin AS, Siedler MR.

Gastroenterology. 2016 Jul;151(1):45. doi: 10.1053/j.gastro.2016.05.041. Epub 2016 May 27. No abstract available.

PMID:
27240901
27.

Development of a Practical Model for Targeting Patient Decision Support Interventions to Promote Colorectal Cancer Screening in Vulnerable Populations.

Brenner AT, Gupta S, Ko LK, Janz N, Inadomi JM.

J Health Care Poor Underserved. 2016;27(2):465-78. doi: 10.1353/hpu.2016.0090.

28.

Racial/Ethnic Disparities in Colorectal Cancer Screening Across Healthcare Systems.

Burnett-Hartman AN, Mehta SJ, Zheng Y, Ghai NR, McLerran DF, Chubak J, Quinn VP, Skinner CS, Corley DA, Inadomi JM, Doubeni CA; PROSPR Consortium.

Am J Prev Med. 2016 Oct;51(4):e107-15. doi: 10.1016/j.amepre.2016.02.025. Epub 2016 Apr 1.

29.

Risks Associated With Anesthesia Services During Colonoscopy.

Wernli KJ, Brenner AT, Rutter CM, Inadomi JM.

Gastroenterology. 2016 Apr;150(4):888-94; quiz e18. doi: 10.1053/j.gastro.2015.12.018. Epub 2015 Dec 18.

30.

Adherence to Competing Strategies for Colorectal Cancer Screening Over 3 Years.

Liang PS, Wheat CL, Abhat A, Brenner AT, Fagerlin A, Hayward RA, Thomas JP, Vijan S, Inadomi JM.

Am J Gastroenterol. 2016 Jan;111(1):105-14. doi: 10.1038/ajg.2015.367. Epub 2015 Nov 3.

31.

Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium.

Sharma P, Katzka DA, Gupta N, Ajani J, Buttar N, Chak A, Corley D, El-Serag H, Falk GW, Fitzgerald R, Goldblum J, Gress F, Ilson DH, Inadomi JM, Kuipers EJ, Lynch JP, McKeon F, Metz D, Pasricha PJ, Pech O, Peek R, Peters JH, Repici A, Seewald S, Shaheen NJ, Souza RF, Spechler SJ, Vennalaganti P, Wang K.

Gastroenterology. 2015 Nov;149(6):1599-606. doi: 10.1053/j.gastro.2015.08.007. Epub 2015 Aug 19.

32.

Association of Visceral Fat Area, Smoking, and Alcohol Consumption with Reflux Esophagitis and Barrett's Esophagus in Japan.

Matsuzaki J, Suzuki H, Kobayakawa M, Inadomi JM, Takayama M, Makino K, Iwao Y, Sugino Y, Kanai T.

PLoS One. 2015 Jul 30;10(7):e0133865. doi: 10.1371/journal.pone.0133865. eCollection 2015.

33.

An Accurate Cancer Incidence in Barrett's Esophagus: A Best Estimate Using Published Data and Modeling.

Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, de Koning HJ, Meester R, Inadomi JM, van Ballegooijen M.

Gastroenterology. 2015 Sep;149(3):577-85.e4; quiz e14-5. doi: 10.1053/j.gastro.2015.04.045. Epub 2015 Apr 29.

34.

The Role of Gastroesophageal Reflux and Other Factors during Progression to Esophageal Adenocarcinoma.

Hazelton WD, Curtius K, Inadomi JM, Vaughan TL, Meza R, Rubenstein JH, Hur C, Luebeck EG.

Cancer Epidemiol Biomarkers Prev. 2015 Jul;24(7):1012-23. doi: 10.1158/1055-9965.EPI-15-0323-T. Epub 2015 Apr 30.

35.

Cost considerations in implementing a screening and surveillance strategy for Barrett's oesophagus.

Inadomi JM.

Best Pract Res Clin Gastroenterol. 2015 Feb;29(1):51-63. doi: 10.1016/j.bpg.2014.12.002. Epub 2014 Dec 18. Review.

PMID:
25743456
36.

Comparing the effectiveness of competing tests for reducing colorectal cancer mortality: a network meta-analysis.

Elmunzer BJ, Singal AG, Sussman JB, Deshpande AR, Sussman DA, Conte ML, Dwamena BA, Rogers MA, Schoenfeld PS, Inadomi JM, Saini SD, Waljee AK.

Gastrointest Endosc. 2015 Mar;81(3):700-709.e3. doi: 10.1016/j.gie.2014.10.033.

37.

Gastric cancer in asian american populations: a neglected health disparity.

Taylor VM, Ko LK, Hwang JH, Sin MK, Inadomi JM.

Asian Pac J Cancer Prev. 2014;15(24):10565-71. Review.

38.

Quality indicators for EGD.

Park WG, Shaheen NJ, Cohen J, Pike IM, Adler DG, Inadomi JM, Laine LA, Lieb JG 2nd, Rizk MK, Sawhney MS, Wani S.

Gastrointest Endosc. 2015 Jan;81(1):17-30. doi: 10.1016/j.gie.2014.07.057. Epub 2014 Dec 2. Review. No abstract available.

PMID:
25480101
39.

Quality indicators for EGD.

Park WG, Shaheen NJ, Cohen J, Pike IM, Adler DG, Inadomi JM, Laine LA, Lieb JG 2nd, Rizk MK, Sawhney MS, Wani S.

Am J Gastroenterol. 2015 Jan;110(1):60-71. doi: 10.1038/ajg.2014.384. Epub 2014 Dec 2. No abstract available.

PMID:
25448872
40.

Gut epithelial barrier and systemic inflammation during chronic HIV infection.

Somsouk M, Estes JD, Deleage C, Dunham RM, Albright R, Inadomi JM, Martin JN, Deeks SG, McCune JM, Hunt PW.

AIDS. 2015 Jan 2;29(1):43-51. doi: 10.1097/QAD.0000000000000511.

41.

The Impact of Uncertainty in Barrett's Esophagus Progression Rates on Hypothetical Screening and Treatment Decisions.

Kroep S, Lansdorp-Vogelaar I, van der Steen A, Inadomi JM, van Ballegooijen M.

Med Decis Making. 2015 Aug;35(6):726-33. doi: 10.1177/0272989X14551640. Epub 2014 Oct 2.

42.

Patient trust in physician influences colorectal cancer screening in low-income patients.

Gupta S, Brenner AT, Ratanawongsa N, Inadomi JM.

Am J Prev Med. 2014 Oct;47(4):417-23. doi: 10.1016/j.amepre.2014.04.020. Epub 2014 Jul 29.

43.

Exploring the recent trend in esophageal adenocarcinoma incidence and mortality using comparative simulation modeling.

Kong CY, Kroep S, Curtius K, Hazelton WD, Jeon J, Meza R, Heberle CR, Miller MC, Choi SE, Lansdorp-Vogelaar I, van Ballegooijen M, Feuer EJ, Inadomi JM, Hur C, Luebeck EG.

Cancer Epidemiol Biomarkers Prev. 2014 Jun;23(6):997-1006. doi: 10.1158/1055-9965.EPI-13-1233. Epub 2014 Apr 1.

44.

Non-physician performance of lower and upper endoscopy: a systematic review and meta-analysis.

Day LW, Siao D, Inadomi JM, Somsouk M.

Endoscopy. 2014 May;46(5):401-10. doi: 10.1055/s-0034-1365310. Epub 2014 Mar 13. Review.

45.

Greater loss of productivity among Japanese workers with gastro-esophageal reflux disease (GERD) symptoms that persist vs resolve on medical therapy.

Suzuki H, Matsuzaki J, Masaoka T, Inadomi JM.

Neurogastroenterol Motil. 2014 Jun;26(6):764-71. doi: 10.1111/nmo.12319. Epub 2014 Feb 25.

PMID:
24602100
46.

A combined paging alert and web-based instrument alters clinician behavior and shortens hospital length of stay in acute pancreatitis.

Dimagno MJ, Wamsteker EJ, Rizk RS, Spaete JP, Gupta S, Sahay T, Costanzo J, Inadomi JM, Napolitano LM, Hyzy RC, Desmond JS.

Am J Gastroenterol. 2014 Mar;109(3):306-15. doi: 10.1038/ajg.2013.282.

47.

How to recognize a good guideline.

Inadomi JM, Weinberg DS.

Gastroenterology. 2013 Dec;145(6):1179-81. No abstract available.

PMID:
24409478
48.

Esophageal varices on computed tomography and subsequent variceal hemorrhage.

Somsouk M, To'o K, Ali M, Vittinghoff E, Yeh BM, Yee J, Monto A, Inadomi JM, Aslam R.

Abdom Imaging. 2014 Apr;39(2):251-6. doi: 10.1007/s00261-013-0057-x.

49.

Comparing trends in esophageal adenocarcinoma incidence and lifestyle factors between the United States, Spain, and the Netherlands.

Kroep S, Lansdorp-Vogelaar I, Rubenstein JH, Lemmens VE, van Heijningen EB, Aragonés N, van Ballegooijen M, Inadomi JM.

Am J Gastroenterol. 2014 Mar;109(3):336-43; quiz 335, 344. doi: 10.1038/ajg.2013.420. Epub 2013 Dec 17.

50.

American Gastroenterological Association Institute technical review on the use of thiopurines, methotrexate, and anti-TNF-α biologic drugs for the induction and maintenance of remission in inflammatory Crohn's disease.

Dassopoulos T, Sultan S, Falck-Ytter YT, Inadomi JM, Hanauer SB.

Gastroenterology. 2013 Dec;145(6):1464-78.e1-5. doi: 10.1053/j.gastro.2013.10.046. Review. No abstract available.

PMID:
24267475

Supplemental Content

Loading ...
Support Center